1 of 134

Cardiac Lecture Series

Mohamed Ismaeil, MD

Inhaled anesthetics and gases

2 of 134

History

History

3 of 134

4 of 134

Physical properties of inhaled anaesthetics and gases

5 of 134

PHYSICAL PROPERTIES

  • Chemical Structure
  • Boiling Point and Vapor Pressure
  • Solubility
  • Meyer Overton Hypothesis

6 of 134

What are Inhaled Anesthetics

  • Halothane: Alkane
  • Enflurane: Methyl-ethyl ether
  • Isoflurane: Methyl-ethyl ether
  • Sevoflurane: Methyl-isopropyl ether
  • Desflurane: Methyl-ethyl ether
  • Nitrous oxide: Inorganic gas
  • Xenon: Noble gas

7 of 134

Structure of Diethyl Ether

8 of 134

N=N=O

Nitrous Oxide

Halothane

Enflurane

F H

F – C – C* – Br

F Cl

F F F

Cl C* C O C H

H F F

F H F

F– C – C* – O – C – H

F Cl F

Isoflurane

F F H H

C

F C O C F

F C H

F F

Sevoflurane

F H F

F – C – C* – O – C – H

F F F

Desflurane

9 of 134

Effect of Chemical Structure on Physical Properties

  • Halogenation reduces flammability
  • Fluorination reduces solubility
  • Fluorination decreases potency
  • Substitution of Cl for F (isoflurane vs. desflurane):
    • ↓Solubility
    • ↓Potency
    • ↑ Vapor Pressure and ↓ Boiling Point
  • Substitution of Cl for H/Br increases potency
  • Progression of potency: H/Br > Cl > F

10 of 134

Vapor Pressure and Boiling Point

  • All inhaled anesthetics liquid at 20 0C
  • Vapor Pressure: Pressure exerted by the molecules of the vapor phase at equilibrium of molecules moving in and out of liquid phase
  • ↑ Temperature→↑ Vapor Pressure
  • Boiling Point: Temperature at which vapor pressure equals atmospheric pressure

Vapor Pressure dependent on temperature and physical characteristics of liquid, independent of atmospheric pressure

11 of 134

BP and VP of Inhaled Anesthetics

Agent

BP (0C)

VP (20 0C)

Halothane

50

243

Enflurane

56

175

Isoflurane

48

238

Sevoflurane

58

160

Desflurane

23

664

Nitrous Oxide

-89

Xenon

-107

12 of 134

Significance of Boiling Point

  • Variable Bypass Vaporizer: Halothane, enflurane, isoflurane, sevoflurane Datex Ohmeda Tec 4,5,7 or North American Drager Vaporizer 19.n and 20.n
  • Tec 6 Vaporizer: Desflurane Electronically heated, thermostatically controlled, pressurized, electromechanically coupled, dual circuit gas-vapor blender

13 of 134

14 of 134

Diffusion of Gases Through Liquids

When a gas comes into contact with a liquid such as water, there is a tendency for the gas to dissolve in the liquid.

At equilibrium the concentration of a gas in the liquid is determined by its partial pressure in the gas and by its solubility in the liquid.

This relationship is described by Henry’s law.

Concentration of dissolved gas = Partial pressure of gas x Solubility coefficient

15 of 134

Diffusion of Gases Through Liquids

 The solubility coefficient is a measure of how easily the gas dissolves in the liquid. In water the solubility coefficient for oxygen is 0.024, and for carbon dioxide it is 0.57.

Thus carbon dioxide is approximately 24 times as soluble in water as oxygen. Gases do not actually produce partial pressure in a liquid as they do when in the gaseous state.

16 of 134

Diffusion of Gases Through Liquids

However, knowing the concentration of the gas in liquid, it is possible to determine mathematically (general gas law) its partial pressure as if it were in a gaseous state.

Because the partial pressure thus calculated is a measure of concentration, it can be used to determine the direction of diffusion of gas through a liquid: gases move from areas of higher to areas of lower partial pressure.

17 of 134

Solubility of Inhaled Anesthetics

  • Solubility is defined in terms of the partition coefficient
  • Partition coefficient is the ratio of the amount of substance present in one phase compared with another, the two phases being of equal volume and in equilibrium
  • Or it can be defined as the relative concentrations of anesthetic for two phases when the partial pressure of two phases is equal.

18 of 134

Solubility of Inhaled Anesthetics

  • Ideal inhaled anesthetics should have low blood/gas and low tissue/blood solubility and low solubility in plastic and rubber
  • Low solubility means rapid induction and emergence and more precise control
  • Anesthesia related to partial pressure of gas in brain
  • More molecules of a soluble gas/agent required before increasing partial pressure in brain
  • Induction/recovery: Desflurane>Sevoflurane> Isoflurane.

19 of 134

Partition Coefficients of Inhaled Anesthetics

Halothane

Enflurane

Isoflurane

Sevoflurane

Desflurane

N2O

Blood/

Gas

2.54

1.8

1.4

0.69

0.42

0.47

Brain/

Blood

1.9

-

1.6

1.7

1.3

0.5

Fat/

Blood

51

-

45

48

27

2.3

20 of 134

The blood: gas pc is useful, really.

  • Anesthesia is related to the partial pressure of the gas in the brain.
  • If a drug is dissolved in blood, it isn’t available as a gas
  • More molecules of a soluble gas are required to saturate liquid phase before increasing partial pressure
  • Speed of onset/offset closely related to solubility
  • The lower the blood:gas pc - the faster the onset

21 of 134

FA/FI Ratio of Inhaled Anesthetics

22 of 134

Effect of Rubber and Plastic Components

  • Rubber or plastic components may remove agents
  • Significant problem with obsolete agent-methoxyflurane
  • Minor problem-halothane and isoflurane
  • No problem-N2O, desflurane, sevoflurane

23 of 134

Odor

  • Halothane: Sweet
  • Isoflurane: Pungent, ethereal
  • Enflurane: Pungent, ethereal
  • Desflurane: Pungent, ethereal
  • Sevoflurane: None, sweet
  • Nitrous Oxide: None, sweet
  • Xenon: None

24 of 134

Respiratory Irritation

2 MAC Desflurane: 75%

2 MAC Isoflurane : 50%

2 MAC Sevoflurane: 0%

1MAC: No irritation with any of three

Sevofluane: Agent of choice for induction

25 of 134

Products of Anesthetic Degradation

Anesthetic

Moist Absorbent

Dry

Absorbent

Desflurane

None

CO

Isoflurane

None

CO

Sevoflurane

Compound A

Compound A

26 of 134

Compound A / BCDFE

Pentafluoroisopropenyl fluoromethyl ether (PIFE, C4H2F6O)

Extraction of acidic proton in presence of strong base (KOH, NaOH)

Baralyme > Soda lime

Production inversely related to FGF

Production directly related to absorbent temperature

Deprotonation of halothane by soda lime-BCDFE (2-bromo-2-chloro-1,1-difluoro ethylene)

27 of 134

Xenon

Inert gas with anesthetic properties

Normal constituent of atmospheric air at a concentration of <0.086 ppm

Removed by fractional distillation of liquefied air

Highly insoluble

Blood/gas Partition Coefficient 0.14

Oil/gas Partition Coefficient 1.9

Environment friendly

Density 5.8 gm/L (N2O 1.53 ; Air 1).

Greater density→ ↑ Airway resistance

28 of 134

FGF vs Compound A

29 of 134

Temperature vs CompoundA

30 of 134

Nitrous Oxide

Clear, colorless, odorless gas

Molecular weight: 44

Supplied through pipeline or pressurized cylinders

BP: -890C

Critical temperature: 36.5 0C

Critical Pressure: 73 bars

Specific gravity: 1.53 at 0C

Filling ratio: 0.65

31 of 134

Effect of Nitrous Oxide on �Closed Gas Spaces

Nitrogen: Blood/gas partition coefficient 0.015

Nitrous Oxide: 0.47

N2O leaves blood 34 times faster than N2 is absorbed

Theoretical limit to increase in volume is a function of alveolar nitrous oxide concentration.

At equilibrium, concentration of N2O in closed gas space equal alveolar concentration.

Alveolar concentration of 50% N2O may double volume of gas space

32 of 134

Pharmacokinetics and pharmacodynamics

33 of 134

Pharmacokinetics

34 of 134

UPTAKE AND DISTRIBUTION

  • Goal: To develop and maintain a satisfactory partial pressure or tension of anesthetic at the site of anesthetic action in brain
  • Delivered>Inspired>Alveolar>Arterial>Brain
  • Concentration= Partial pressure/barometric pressurex100
  • Brain with its high perfusion per gram rapidly equilibrates with anesthetic partial pressure in blood

35 of 134

Factors Affecting Inspiratory Concentration (FI)

1. Fresh gas flow rate

2. The volume of the breathing circuit

3. Any absorption by the machine or breathing circuit

  • The higher the fresh gas flow rate
  • The smaller the breathing system volume
  • The lower the circuit absorption

  • The closer the inspired gas concentration to the fresh gas concentration
  • Faster induction and recovery times

36 of 134

Uptake and distribution

  • Anesthesia depends upon brain partial pressure
  • Alveolar partial pressure (PA) = Pbrain
  • The faster PA approaches the desired level the faster the patient is anesthetized
  • PA is a balance between delivery of drug to the alveolus and uptake of that drug into the blood
  • Time for an analogy

37 of 134

To induce anesthesia the bucket (PA) must be full. Unfortunately the bucket has a leak (uptake). To fill the bucket you must either (a) pour it in faster (increase delivery) or (b) slow down the leak (decrease uptake).

a

b

38 of 134

Factors Affecting Alveolar Concentration (FA)

1. Uptake

2. Ventilation

3. Concentration

39 of 134

Uptake

The slower of the rate of induction

The slower the rate of rise of the alveolar concentration

The greater the difference between FA and FI (the lower the FA/FI ratio)

The greater the uptake

Anesthetic agents are taken up by pulmonary circulation during induction 🡪 FA/FI < 1

40 of 134

41 of 134

Factors Affecting Anesthetic Uptake

1. Solubility in the blood

2. Alveolar blood flow

3. The difference in partial pressure between alveolar gas and venous blood

42 of 134

Solubility in Blood

Partition coefficients: the ratio of the concentration of anesthetic gas in each of two phases at equilibrium (equal partial pressures)

The higher the blood/gas coefficient

  • The greater the solubility
  • The greater its uptake by pulmonary circulation
  • Alveolar partial pressure rises more slowly
  • Induction is prolonged

43 of 134

44 of 134

Alveolar Blood Flow

Equal to cardiac output (in the absence of pulmonary shunting)

Cardiac output increases

Anesthetic uptake increases

The rise in alveolar partial pressure slows

Induction is delayed

Low-output states 🡪 will affect the less soluble agents more

Myocardial depressant (halothane) 🡪 lowering cardiac output 🡪 positive feedback loop

45 of 134

The Partial Pressure Difference between Alveolar Gas and Venous Blood

Depends on tissue uptake

Factors affecting transfer of anesthetic from blood to tissue:

1. Tissue solubility (tissue/blood partition coefficient)

2. Tissue blood flow

3. The difference in partial pressure between arterial blood and tissue

46 of 134

47 of 134

48 of 134

Ventilation

Increasing alveolar ventilation 🡪 constantly replacing anesthetic taken up by bloodstream 🡪 better maintenance of alveolar concentration

Ventilation depressant (halothane) 🡪 decrease the rate of rise in alveolar concentration 🡪 negative feedback loop

49 of 134

Concentration

  • Concentration effect

1. Concentrating effect

2. Augmented inflow effect

  • Second gas effect

20

100

80

100

50% uptake

50% uptake

10

40

60

90

20%

80%

67%

11%

X 4

X 6

2

10

32

40

20%

80%

72

100

12

100

12%

72%

50 of 134

Factors Affecting Arterial Concentration (Fa)

  • Ventilation/perfusion mismatch increase the alveolar-arterial difference
  • An increase in alveolar partial pressure
  • A decrease in arterial partial pressure

51 of 134

V/Q distribution and uptake

Ventilation < perfusion

blood leaving shunt dilutes PA from normal lung

induction with low solubility agent will be delayed

little difference with soluble agents (slow anyway)

Ventilation > perfusion

uptake is decreased which enhances rise in FA

may speed induction for soluble agents

less difference with low solubility agents (fast anyway)

52 of 134

Factors Affecting Elimination

  • Elimination

1. Biotransformation: cytochrome P-450

2. Transcutaneous loss: insignificant

3. Exhalation: most important

  • Factors speed recovery

Elimination of rebreathing, high fresh gas flows, low anesthetic-circuit volume, low absorption by anesthetic circuit, decreased solubility, high cerebral blood flow, increased ventilation, length of time

  • Diffusion hypoxia: elimination of nitrous oxide is so rapid that alveolar O2 and CO2 are diluted

53 of 134

Metabolism

Drug

Liver

Enzyme

Kidney

Halothane

25%

CYP2E1, CYP2A6, CYP3A4

minimal

Sevoflurane

5%

CYP2E1

<1%, Some metabolism

Isoflurane

0.025%

CYP2E1

none

Desflurane

minimal

CYP2E1?

none

Enflurane

<1%

CYP2E1 (minor)

2%, Major place, F- toxicity no longer on market

54 of 134

Pharmacodynamics

55 of 134

56 of 134

Mechanism of Action

We don’t know… much, but let me tell you about what we do know…

57 of 134

Meyer-Overton hypothesis

The MAC of a volatile substance is inversely proportional to its lipid solubility (oil:gas coefficient) , in most cases. This is the Meyer-Overton hypothesis.

MAC is inversely related to potency i.e. high mac equals low potency.

The hypothesis correlates lipid solubility of an anaesthetic agent with potency (1/MAC) and suggests that onset of anaesthesia occurs when sufficient molecules of the anaesthetic agent have dissolved in the cell's lipid membranes, resulting in anaesthesia.

58 of 134

Critical Volume Hypothesis

The Critical Volume Hypothesis is a modification of Meyer-Overton that states anesthesia occurs when a “critical region” volume is sufficiently changed by a certain degree that anesthesia results

- This also doesn’t seem to be true

Myer-Overton Rule predicts/implies that anesthesia will occur when a specific number of anesthetic molecules dissolve (implies actual binding sites)

- This doesn’t seem to be true

59 of 134

Membrane Hypotheses

  • Some membrane channels behavior is changed by anesthetic agents
      • Some channels slowed
      • Some channels sped up
      • Different channels different effect with different agents
  • Postulated that lipid bilayer may be site of action
      • Lipid permeability is changed
      • Synaptic vesicles behavior changes
      • Thickness of lipid bilayer is changed - thicker

60 of 134

Membrane Hypotheses

  • Proteins are site of actions
      • Ligand gated ion channel behavior changes
        • neurotransmitters
      • Voltage gated channel behavior changes
        • Ion channels
      • Metabotrobic and G-proteins are affected
        • Serotonin
        • Glutamate
      • Non-synaptic proteins

61 of 134

Receptor Theory

  • Inhaled anesthetic agents interact with many neuronal cell surface proteins
  • GABA receptor is thought to be a likely target
  • GABAA sub-unit is thought to be area of interest – not all GABAA are the same
  • GABA receptors containing alpha-5 sub-unit are also implicated
  • GABA receptors outside the synapse are also thought to be implicated

  • Orser B, Lifting the fog around anesthesia, Scientific American, June 2007, pp. 54-61.

62 of 134

Mechanism – Bottom Line

No one knows

Likely more than one site

Neuronal transmission is disrupted

Pre-synaptic, post-synaptic and extra synaptic effects are found

63 of 134

MAC

Minimum Alveolar Concentration = MAC

Anesthetic potency is measured in MAC

1 MAC is the Minimum Alveolar Concentration at which 50% of humans have no response (movement) to surgical stimulus (skin incision)

MACawake is the alveolar concentration when 50% of persons will awake to vocal stimulus

MAC is directly proportional to the partial pressure of the anesthetic agent in the CNS

MAC is consistent within a species and between species

MAC is different for each inhaled agent

64 of 134

MAC

Activity

Level of MAC

Awake

< 0.2

Memory and Learning

0.3 to 0.6

Anesthesia

0.9 to 3.0

No Movement

1.2 to 1.4

65 of 134

MAC

66 of 134

MAC

  • MAC decreases with decreasing body temperature
  • MAC increases with increasing pressure
      • more anesthetic agent required higher pressures to achieve same MAC
  • Ion concentrations in CNS alter MAC
      • Na – MAC increases with concentration
      • K – no effect
      • Ca – no effect
      • Mg – inversely proportional increase with concentration
  • MAC decreases with age (greatest at 6 months)
  • 6% decrease in MAC per decade of age
  • MAC is altered by other drugs
  • MAC decreases as patient medical condition deteriorates

67 of 134

MAC

Agent

[agent] 1 MAC

(ED50, STP)

Halothane

0.75 %

Isoflurane

1.46 %

Sevoflurane

1.80%

Desflurane

6.60 %

Nitrous Oxide

104%

68 of 134

Factors increasing MAC

Hyperthermia

Chronic ETOH abuse

Hypernatremia

Increased CNS transmitters

MAOI

Amphetamine

Cocaine

Ephedrine

L-DOPA

69 of 134

Factors decreasing MAC

  • Narcotics
  • Ketamine
  • Benzodiazepines
  • 2 agonists
  • LiCO3
  • Local anesthetics
  • ETOH (acute)
  • And many more...
  • Increasing age
  • Hypothermia
  • Hyponatremia
  • Hypotension (MAP<50mmHg)
  • Pregnancy
  • Hypoxemia (<38 mmHg)
  • O2 content (<4.3 ml O2/dl)
  • Metabolic acidosis

70 of 134

71 of 134

Clinical pharmacology

72 of 134

Cardiovascular Effects

  • Heart Rate

Halthane reduces HR

Sevo and Enf are neutral

Des >> Iso can cause an Initial tachycardia

      • Heart rate eventually slows
      • Initial SNS response leading to catecholamine release
      • Dose dependent effect
      • Rapid increases in MAC
      • Rate of administration plays a role

73 of 134

Cardiovascular Effects

Contractility

All agents are depressants

At 1 MAC the approximatel order is:

Halo = Enfl >> Des = Iso = Sevo

    • Cardiac Output is fairly well preserved

Des and Iso > rest

    • Baroreceptor reflexes are preserved

74 of 134

Cardiovascular Effects

Vasculature

All inhaled agents are smooth muscle relaxants

All cause vasodilation (decreased SVR)

Variable effects on different vascular

leading to hypotension

via Protein Kinase C inhibition – cAMP and Ca Troponin binding

Life threatening hypotension can result at high enough doses – threshold varies for each patient

    • ALL decrease SVR except Nitrous Oxide
    • Some evidence that Inhaled anesthetics are cardio-protective following ischemic insult

75 of 134

Cardiovascular Effects

All inhaled agents are cardio toxic will lead to death at high enough concentrations

Arrhythmias are induced by all anesthetic agents

    • Halothane is worst
    • Potentates Catecholamine induced arrhythmias
    • Children are less affected than adults
    • Lidocaine has been shown to double ED50 at 1.25 MAC

ED50 of epinephrine at 1.25 MAC

    • halothane 2.1 μg•kg-1
    • isoflurane 6.9 μg•kg-1
    • enflurane 10.9 μg•kg-1

76 of 134

Cardiovascular Effects

  • Coronary Blood Flow

Isoflurane shown to be potent coronary vasodilator

Sevoflurane and Desflurane seem to be less potent in animal models (not all tissue beds behave the same)

Concern that blood can be directed away from stenotic coronaries

Coronary Steal theoretically possible

      • One vessel highly stenosed
      • Practically, does not seem to be a real problem

77 of 134

Respiratory Effects

Patients will only willingly breath Sevoflurane and Halothane

All other agents are respiratory irritants

Tidal Volume is decreased

Respiratory rate is increased

Minute ventilation is decreased

No change in mucociliary clearance

78 of 134

Respiratory Effects

Chemoreceptors

Response to CO2 blunted

Apneic Threshold raised

PCO2 raised during spontaneous ventilation

      • Enf > Des = Iso > Sevo = Halo

Hypoxic drive abolished early at about 0.1 MAC

79 of 134

Respiratory Effects

Musculature

  • All agents cause smooth muscle relaxation

Reduction in Vagal Tone

Inhibit Protein Kinase C

      • cAMP reduction
      • Decreased binding of Troponin to Ca2+ ?

Dose Dependent reduction in Airway Resistance (RAW) occurs

  • Useful in Treatment of Status Asmaticus

Isoflurane thought best

80 of 134

Respiratory Effects

PVR is decreased

Hypoxic pulmonary vasoconstriction impaired

Increased shunting

Gas exchange is less efficient (decreased FRC, increased shunt)

Shunt and oxygenation largely not affected by one lung ventilation

Changes in PVR

Difficult to assess

Effects of many things affect numbers

Positon

Cardiac Output

PA pressure

Nitrous oxide worsens pulmonary hypertension - causes increased PVR

81 of 134

Central nervous system effects

  • The CMRO2 is decreased by anesthetic agents
  • Increased Cerebral Blood Flow

auto regulation of cerebral blood flow is impaired

  • Increased ICP

Via blood flow

Via induced hypercapnea

  • Seizure activity may be increased (Enflurane at 2.0 MAC)
  • Ventilatory Responses Blunted

Sleep apnea

Narcotics add synergistically

Benzodiazepines add synergistically

82 of 134

Central nervous system effects

  • EEG

Decreased Amplitude

Increased Latency

  • Neurologic function is effectively stopped

EEG is flat line at high concentrations

Useful in the treatment of status epilepticus

Must give a very deep anesthetic

  • Memory?

Do deep anesthetics cause memory impairment?

  • EEG monitoring

BIS = Bispectral Index (Aspect Medical)

uses EEG changes to monitor depth of anesthesia

AKA – BIS, Entropy, Evoked Potentials

83 of 134

Central nervous system effects

Intraoperative Awareness

Estimated at 0.15% of all cases

Risk Factors

    • Paralytic use
    • Type of Surgery
      • Cardiac
      • Obstetrics (GA for C/S)
      • Trauma
    • Poor Machine Maintenance

Patient Factors

    • Age
    • Gender
    • Substance Use/Abuse
    • Underlying medical Condition

Drugs Used

    • Nitrous, Ketamine, Xenon, TIVA
    • Less Problematic with inhaled AA

84 of 134

Kidney Effects

Kidney

  • Dose dependant decreases in:

Renal blood flow

GFR

Urine Output

  • Related to changes in Cardiac Output and BP not ADH

85 of 134

Central nervous system effects

Some agents (enflurane, sevoflurane) can be toxic due to F- production during metabolism in liver or in the kidney

Fluoride nephrotoxicity

Sevoflurane produces Compound A which is a renal toxin

    • Not known in humans

Anesthetized patients are heavily dependent on renin - angiotensin system to regulate volume status

86 of 134

Other Organs

  • Muscle

Potentate NMBA

Skeletal Muscle is relaxed by inhaled AA

MH

87 of 134

Liver

Hepatic blood flow decreased

    • Drug metabolism is altered (slowed)
    • Some agents are potentially hepatotoxic

Most agents cause a transient increase in LFT’s

Cause is unknown

    • Hypoxia?
    • Reactive intermediates?

88 of 134

Obstetrics

Nitrous Oxide little effect acutely

    • Dose Dependent
    • Uterine relaxation
    • Decreased Uterine blood flow

Halogenated inhaled AA

89 of 134

90 of 134

91 of 134

92 of 134

93 of 134

94 of 134

Waking Up

  • Agent used
  • Length of anesthetic
  • Patient

Age

Mental state (MR, Alzheimer's…)

Medical condition (sepsis, Parkinson’s)

Other Medications

      • benzodiazepines, opiates, neuroleptics, local anesthetics, intoxicants
  • Obesity

All agents, especially soluble agents, dissolve in fat creating a depot of drug

      • Sleep apnea
      • Airway obstruction

95 of 134

96 of 134

Waking Up in OR

97 of 134

Waking Up – Complex Tasks

98 of 134

Waking Up – Level of MAC

99 of 134

Nitrous Oxide

  • The only inorganic anesthetic gas in clinical use
  • Colorless and odorless
  • Cardiovascular

Depress myocardial contractility

Arterial BP, CO, HR: unchanged or slightly↑ due to stimulation of catecholamines

Constriction of pulmonary vascular smooth muscle  increase pulmonary vascular resistance

Peripheral vascular resistance: not altered

Higher incidence of epinephrine-induced arrhythmia

100 of 134

Nitrous Oxide

  • Respiratory

Respiratory rate: ↑

Tidal volume: ↓

Minute ventilation, resting arterial CO2: minimal change

Hypoxic drive (ventilatory response to arterial hypoxia): depressed

  • Cerebral

CBF, cerebral blood volume, ICP: ↑

Cerebral oxygen consumption (CMRO2): ↑

101 of 134

Nitrous Oxide

  • Neuromuscular

Not provide significant muscle relaxation

Not a triggering agent of malignant hyperthermia

  • Renal

Increase renal vascular resistance

Renal blood flow, glomerular filtration rate, U/O: ↓

  • Hepatic

Hepatic blood flow: ↓

  • Gastrointestinal

Postoperative nausea and vomiting

102 of 134

Nitrous Oxide

  • Biotransformation & toxicity

Almost all eliminated by exhalation

Biotransformation < 0.01%

Irreversibly oxidize Co in vit.B12  inhibit vit.B12-dependent enzymes  interfere myelin formation, DNA synthesis

Prolonged exposure  bone marrow suppression, neurological deficiencies

Avoided in pregnant patients

103 of 134

Nitrous Oxide

Contraindications

N2O diffuse into the cavity more rapidly than air (principally N2) diffuse out

Pneumothorax, air embolism, acute intestinal obstruction, intracranial air, pulmonary air cysts, intraocular air bubbles, tympanic membrane grafting

Avoided in pulmonary hypertension

Drug interactions

Due to high MAC, combination with more potent agents  decrease the requirement of other agents

Potentiates neuromuscular blockade

104 of 134

Halothane

Halogenated alkane

Cardiovascular

Direct myocardial depression 🡪 dose-dependent reduction of arterial BP

Coronary artery vasodilator, but coronary blood flow↓ due to systemic BP↓

Blunt the reflex: hypotension inhibits baroreceptors in aortic arch and carotid bifurcation 🡪 vagal stimulation↓🡪 compensatory rise in HR

Sensitzes the heart to the arrhythmogenic effects of epinephrine (<1.5μg/kg)

Systemic vascular resistance: unchanged

105 of 134

Halothane

  • Respiratory

Rapid, shallow breathing

Alveolar ventilation: ↓

Resting PaCO2: ↑

Hypoxic drive: severely depressed

A potent bronchodilator, reverses asthma-induced bronchospasm

Depress clearance of mucus  promoting postoperative hypoxia and atelectasis

106 of 134

Halothane

Cerebral

    • - Dilating cerebral vessels  cerebral vascular resistance↓ CBF↑
    • - Blunt autoregulation (the maintenance of constant CBF during changes in arterial BP)
    • - ICP: ↑, prevented by hyperventilation prior to administration of halothane
    • - Metabolic oxygen requirement: ↓

Neuromuscular

    • - Relaxes skeletal muscle
    • - A triggering agent of malignant hyperthermia

107 of 134

Halothane

  • Renal

Renal blood flow, GFR, U/O: ↓

Part of this can be explained by a fall in arterial BP and CO, preoperative hydration limits these changes

  • Hepatic

Hepatic blood flow: ↓

  • Biotransformation & toxicity

Oxidized in liver by cytochrome P-450

In the absence of O2  hepatotoxic end products

Halothane hepatitis is extremely rare (1/35,000)

108 of 134

Halothane

Contraindications

Unexplained liver dysfunction following previous exposure

No evidence associating halothane with worsening of preexisting liver disease

Intracranial mass lesion, hypovolemic, severe cardiac disease…

  • Drug interactions

Myocardial depression is exacerbation by β-blockers and CCB

With aminophylline  serious ventricular arrhythmia

109 of 134

Isoflurane

Pungent ethereal odor

A chemical isomer of enflurane

Cardiovascular

Minimal cardiac depression

HR: ↑ due to partial preservation of carotid baroreflex

Systemic vascular resistance: ↓🡪 BP: ↓

Dilates coronary arteries 🡪 coronary steal syndrome or drop in perfusion pressure 🡪 regional myocardial ischemia 🡪 avoided in patients with CAD

110 of 134

Isoflurane

  • Respiratory

Respiratory depression, minute ventilation: ↓

Blunt the normal ventilatory response to hypoxia and hypercapnia

Irritate upper airway reflex

A good bronchodilator

  • Cerebral

CBF, ICP: ↑, reversed by hyperventilation

Cerebral metabolic oxygen requirement: ↓

  • Neuromuscular

Relaxes skeletal muscle

111 of 134

Isoflurane

  • Renal

Renal blood flow, GFR, U/O: ↓

  • Hepatic

Total hepatic blood flow: ↓

  • Biotransformation & toxicity

Limited metabolism

  • Contraindications

Severe hypovolemia

  • Drug interactions

Epinephrine (4.5μg/kg)

Potentiate nondepolarizing NMBAs

112 of 134

Desflurane

  • Structure is similar to isoflurane
  • High vapor pressure
  • Low solubility  ultrashort duration of action
  • Moderate potency
  • Cardiovascular

Systemic vascular resistance: ↓ BP: ↓

CO: unchanged or slightly depressed

Rapid increases in concentration lead to transient elevation in HR, BP, catecholamine levels

Not increase coronary artery blood flow

113 of 134

Desflurane

RESPIRATORY

Tidal volume: ↓, respiratory rate: ↑

Alveolar ventilation: ↓, resting PaCO2: ↑

Depress the ventilatory response to ↑PaCO2

Pungency and airway irritation

  • CEREBRAL

Vasodilate cerebral vasculature  CBF, ICP: ↑, lowered by hyperventilation

Cerebral metabolic rate of oxygen: ↓ vasoconstriction  moderate the increase in CBF

114 of 134

Desflurane

Neuromuscular

Dose-dependent decrease in the response to train-of-four and tetanic peripheral nerve stimulation

    • Renal

No evidence of any nephrotoxic effects

    • Hepatic

No evidence of hepatic injury

    • Biotransformations & toxicity

115 of 134

Desflurane

Contraindications

Severe hypovolemia, malignant hyperthermia, intracranial hypertension

Drug interactions

Potentiate nondepolarizing NMBAs

Not sensitize myocardium to arrhythmogenic effects of epinephrine (4.5μg/kg)

Emergence associated with delirium in some pediatric patients

116 of 134

Sevoflurane

  • Nonpungency and rapid increase in alveolar anesthetic concentration  smooth and rapid inhalation inductions in pediatric and adult patients
  • Faster emergence associated with greater incidence of delirium in pediatric populations
  • Cardiovascular

Mildly depress myocardial contractility

Systemic vascular resistance, arterial BP: ↓

CO: not maintained well due to little rise in HR

Prolong QT interval

117 of 134

Sevoflurane

  • Respiratory

Depress respiration

Reverse bronchospasm

  • Cerebral

CBF, ICP: slight ↑

Cerebral metabolic oxygen requirement: ↓

  • Neuromuscular

Adequate muscle relaxation for intubation of children

  • Renal

Renal blood flow: slightly ↓

Associated with impaired renal tubule function

118 of 134

Sevoflurane

  • Hepatic

Portal vein blood flow: ↓

Hepatic artery blood flow: ↑

  • Biotransformation & toxicity

Liver microsomal enzyme P-450

Degraded by alkali (barium hydroxide lime, soda lime), producing nephrotoxic end products (compound A)

Fresh gas flows be at least 2 L/min

Not be used in patients with preexisting renal dysfunction

119 of 134

Sevoflurane

  • Contraindications

Severe hypovolemia, susceptibility to malignant hyperthermia, intracranial hypertension

  • Drug interactions

Potentiate NMBAs

Not sensitize the heart to catecholamine-induced arrhythmias

120 of 134

Metabolism of Inhaled anesthetics and gases��

121 of 134

Metabolism

Drug

Liver

Enzyme

Kidney

Halothane

25%

CYP2E1, CYP2A6, CYP3A4

minimal

Sevoflurane

5%

CYP2E1

<1%, Some metabolism

Isoflurane

0.025%

CYP2E1

none

Desflurane

minimal

CYP2E1?

none

Enflurane

<1%

CYP2E1 (minor)

2%, Major place, F- toxicity no longer on market

122 of 134

Toxicity - Hepatitis

Reported since first use of halogenated anesthetics

Most common cause of post operative jaundice is hematoma resorbtion

“Halothane hepatitis” was reported very shortly after anesthetic introduced

Incidence 1:10 000 with halothane

Usually requires multiple exposures

Most patients given halothane have evidence of liver injury

Not as common with newer anesthetic agents

    • One confirmed case with isoflurane
    • Two case reports with desflurane – some suspect
    • Many with Sevoflurane

Hepatitis and Pancreatitis are known complications of surgery estimated rate ca. 1: 1 000 000

123 of 134

Hepatic Toxicity

  • All inhaled AA can cause hepatic injury in animal studies
  • All inhaled AA have immunohistochemical evidence of binding to hepatocytes
  • Thought that Trifluoroacetic acid metabolites are root cause

Njoku, Anest Analg 1997; 84:173.

124 of 134

Toxicity – Malignant Hyperthermia

  • AD genetic condition with variable penetrance

producing a myopathy

Most patients are aware of family history of condition

More common Europeans (northern)

  • Multiple genes are involved
  • Incidence is 1: 4200-250000 anesthetics

Some patients can receive triggering agents and have no reaction – case reports of up to six exposures prior to MH reaction

Reactions tend to occur at extremes of age

In some cases, a rise in Cpk following anesthesia is the only symptom of condition

  • MH reaction can be caused by other conditions than inhaled anesthetics

Stress

Succinyl choline

125 of 134

Toxicity – Malignant Hyperthermia

  • Genes are involved in intracellular Ca regulation
  • Ryanodyne receptor (dihydropyridine receptor) called RYR1 is thought to be most commonlyinvolved
  • Over 90 mutations known and associated with MH
  • Uncontrolled muscle contraction results from exposure to trigger causing hyper metabolism and skeletal muscle necrosis
  • Resultant rhabdomyolysis causes renal failure
  • Hyperthermia can also cause direct tissue damage
  • Treatment is active cooling of patient and dantrolene (2 mg/Kg doses q 15 minutes up to 10-12 mg/kg)

126 of 134

Fluoride Nephrotoxicty

  • F- is nephrotoxic
  • F- is a byproduct of metabolism in liver and kidney
  • Fluoride nephrotoxicity

[F-] = 50 mol/l

F- opposes ADH leading to polyuria

methoxyflurane 2.5 MAC-hours (no longer used)

enflurane 9.6 MAC-hours

  • Methoxy > enfl > sevo >>> iso >des
  • Results in potentially permanent renal injury
  • Less of a problem with modern anesthetics

127 of 134

Toxins – Sevoflurane and Compound A

Sevoflurane reacts with soda lime used in anesthetic circuit to form “compound A”

fluoromethyl-2-2-difluoro-1-(trifluoromethyl) vinyl ether

Some reports of fires and explosions

Compound A is renal toxin

Large amounts are produced at low gas flow rates

Recommended 2 L / min flow rate

Little evidence of harm unless

    • Low flows
    • Long exposure

Some evidence for changes in markers of damage but not clinically significant

128 of 134

Anesthetics and CO

All anesthetic agents react with soda lime to produce CO

CO is toxic and binds to Hgb in preference to oxygen

Des > enfl >>> iso > sevo >halo

Risk Factors

    • Dryness of soda lime
    • Temperature of soda lime
    • Fi(agent)
    • Barylime produces more than soda lime
    • Barylime removed from market

In general, not clinically significant

No deaths reported

Do you want your anesthetic first Monday morning?

129 of 134

Toxicities – Nitrous Oxide

  • Hematologic:

N2O antagonizes B12 metabolism

inhibition of methionine-synthetase

Decreased DNA production

RBC production depressed post a 2 h N2O exposure ca. 12 later

Leukocyte production depressed if > 12 h exposure

Megoloblastic anemia

Marked depression if exposure longer than 24 hours

130 of 134

Toxicities – Nitrous Oxide

Neurologic

Long term exposure to N2O (vets, dentists and assistants) is hypothesized to result in neurologic disease similar to B12 deficiency

Evidence only shows an association

Increased risk of spontaneous abortion in dental/vetrinarian and OR personel (RR 1.3)

Teratogenic in rats (prolonged exposure of weeks)

131 of 134

Other Toxicity Issues

    • Increased miscarriage rate in pregnant patients given GA
    • Related to underlying medical condition responsible for need for surgery
    • Low birth rate
      • Getting and staying pregnant (veterinary and dental workers less for OR personnel)

Reproduction

    • No evidence that the halogenated agents
    • N2O is suspect risk but not proven in human studies

Teratogenicity

    • OR, dental and vet personnel have increased rates of cancer (1.3-1.9 increase in rate in dental workers)
    • But studies have been negative for AA as cause

Carcinogenicity

132 of 134

Pharmacoeconomics

Anesthesia is usually second most expensive department in hospital

Volatile anesthetic agents ca. 20% of budget

OR time is ~$2400 per hour

Saved OR time needed to pay for bottle

    • Sevoflurane (8 minutes)
    • Desflurane (3 minutes)
    • Isoflurane (<1 minute)
    • Patient turnover in OR and PACU length of stay is a big issue for day surgery
    • If a day surgery pt gets admitted cost is ~$1200 for overnight stay
    • Waiting lists are affected by OR turnover and PACU time
    • These factors need to be considered for agent choice

133 of 134

Pharmacoeconomics

Low flow anesthesia

    • New machines
    • Better monitoring required
    • Most important factor to save inhaled agents

Use of Circle – re-breathing gas circuits

Agent switching during case

    • Use isoflurane for most of case then switch to higher cost agent or switch to isoflurane
    • Using IV agent to facilitate wake-up from isoflurane

Agent Choice

    • Length of Case

134 of 134

THANK YOU!�